Press release
United States Primary Immunodeficiency Diseases Market 2025 | Growth Drivers, Key Players & Investment Opportunities
Primary Immunodeficiency Diseases Market
The Primary Immunodeficiency Diseases Market reached US$ 7.3 billion in 2023 and is expected to reach US$ 13.0 billion by 2031, growing at a CAGR of 7.6% during the forecast period 2024-2031.
Key Development:
United States: Recent Industry Developments
✅ In June 2025, Takeda announced the U.S. FDA approval of GAMMAGARD LIQUID ERC, a ready-to-use liquid immunoglobulin therapy with low IgA content, for patients aged two and older with primary immunodeficiency. Commercialization is expected to begin in 2026.
✅ In May 2025, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and Japan's Agency for Medical Research and Development (AMED) announced joint funding for early-stage research in immunology and infectious diseases, including primary immunodeficiency, under the U.S.-Japan Cooperative Medical Sciences Program.
✅ In April 2025, X4 Pharmaceuticals received U.S. FDA approval for Xolremdi (mavorixafor), the first therapy specifically for WHIM syndrome, a rare genetic immunodeficiency disorder. The treatment demonstrated a 60% reduction in infection rates in clinical trials.
Japan: Recent Industry Developments
✅ In August 2025, Japan's Ministry of Health, Labour and Welfare committed an additional USD 1 million to support the Global Antibiotic Research & Development Partnership (GARDP), aiming to develop new treatments for drug-resistant infections, which may benefit patients with primary immunodeficiency disorders.
✅ In June 2025, Takeda's GAMMAGARD LIQUID ERC received approval from the European Medicines Agency (EMA) as DEQSIGA®, marking a significant step in expanding treatment options for primary immunodeficiency in Europe.
✅ In May 2025, Japan's Agency for Medical Research and Development (AMED) and the U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced joint funding for early-stage research in immunology and infectious diseases, including primary immunodeficiency, under the U.S.-Japan Cooperative Medical Sciences Program.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/primary-immunodeficiency-diseases-market?sb
Primary Immunodeficiency Diseases (PIDs) are a group of genetic disorders in which parts of the immune system are absent or dysfunctional, leading to increased susceptibility to infections, autoimmune conditions, and certain cancers. Management includes immunoglobulin therapy, bone marrow transplantation, gene therapy, and supportive care to improve immune function and patient quality of life.
Recent Mergers and Acquisitions:
United States: Recent M&A Activity
✅ In April 2025, Norgine acquired Theravia, a company specializing in rare disease treatments, including mavorixafor for WHIM syndrome. This acquisition strengthens Norgine's rare disease portfolio, aligning with its growth strategy in immunology.
✅ In May 2024, Biogen announced plans to acquire Human Immunology Biosciences (HI-Bio) for up to $1.8 billion. HI-Bio's leading drug, felzartamab, is being tested for IgA nephropathy, a condition related to primary immunodeficiency.
✅ In June 2024, Vertex Pharmaceuticals acquired Alpine Immune Sciences for $4.9 billion. Alpine's lead candidate, povetacicept, is a potential treatment for IgA nephropathy, expanding Vertex's immunology pipeline.
Japan: Recent M&A Activity
✅ In March 2025, Norgine entered a definitive agreement to acquire Theravia from Mérieux Equity Partners. This acquisition adds key rare disease treatments, including SIKLOS® for sickle cell disease and ORPHACOL® for genetic bile disorders, to Norgine's portfolio.
Key Players:
=> Abbott Laboratories, AstraZeneca, Pfizer, Baxter International, Inc., Bayer, Bristol Myers Squibb, Eli Lilly, Biotest AG, Grifols, CSL Behring among others.
Growth Forecast Projected:
The Global Primary Immunodeficiency Diseases Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Primary Immunodeficiency Diseases Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=primary-immunodeficiency-diseases-market
Key Segments:
➥ By Disease Type: Antibody Deficiency (Agammaglobulinaemia, IgG Subclass Deficiency, Selective IgA Deficiency, Others), Cellular Immunodeficiency (Hyper IgM Syndromes, Ataxia Telangiectasia, Wiskott-Aldrich Syndrome, Others), Innate Immune Disorders (TLR 3 Deficiencies, Natural Killer Cell Deficiency, NF Kappa B Essential Modulator Deficiency, Others)
➥ By Treatment: Immunoglobulin (Ig) Replacement Therapy, Haemopoietic Stem Cell Transplantation, Gene Therapy, Others
➥ By End-User: Hospitals, Specialty Clinics, Academic and Research Centers, Others
Regional Analysis for Primary Immunodeficiency Diseases Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.
Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.
Chapter 3: Offers an in-depth look at the competitive landscape among Primary Immunodeficiency Diseases producers, including revenue shares, strategic moves, and recent mergers and acquisitions.
Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.
Chapters 5 & 6: Analyze Primary Immunodeficiency Diseases revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.
Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.
Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.
Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.
Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/primary-immunodeficiency-diseases-market?sb
FAQ
What is the current size of the Primary Immunodeficiency Diseases Market?
A: In 2023, the Primary Immunodeficiency Diseases Market was valued at US$ 7.3 billion, reflecting its strong industry presence.
Q2: How large is the Primary Immunodeficiency Diseases Market expected to be by 2031?
A: By 2031, industry forecasts suggest the Primary Immunodeficiency Diseases Market will grow to around US$ 13.0 billion, demonstrating significant expansion.
Q3: What is the growth rate of the Primary Immunodeficiency Diseases Market?
A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.6% during the forecast period from 2024 to 2031.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Primary Immunodeficiency Diseases Market 2025 | Growth Drivers, Key Players & Investment Opportunities here
News-ID: 4199451 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Hypercalcemia Treatment Market Growth Driven by Rising Cancer Inci …
The global hypercalcemia treatment market was valued at USD 18.13 billion in 2023 and is projected to reach USD 44.64 billion by 2031, expanding at a CAGR of 11.92% during the forecast period from 2024 to 2031.
The most recent report published by DataM Intelligence indicates that the "Hypercalcemia Treatment Market" is likely to accelerate significantly in the next few years. The Hypercalcemia Treatment Market report gives a purposeful depiction of…
United States Vertical Farming Market Growth Fueled by Smart Agriculture Tech & …
Vertical Farming Market is expected to reach a CAGR of 24.6% during the forecasting period (2024- 2031). The decreasing arable land and depleting natural resources are motivating the crop growing communities towards effective farming practices that follow the 'law of minimum'.
The most recent report published by DataM Intelligence indicates that the "Vertical Farming Market" is likely to accelerate significantly in the next few years. The Vertical Farming Market report…
United States Digital Thermometers Market Expansion Driven by Increasing Home He …
Digital Thermometers Market reached US$ 830.4 million in 2024 and is expected to reach US$ 1,402.86 million by 2033, growing at a CAGR of 6.0% during the forecast period 2025-2033.
The most recent report published by DataM Intelligence indicates that the "Digital Thermometers Market" is likely to accelerate significantly in the next few years. The Digital Thermometers Market report gives a purposeful depiction of the area by the practice for…
United States Kidney Transplant Market Growth Boosted by Rising Organ Donations …
Kidney Transplant Market reached US$ 7.91 Billion in 2024 and is expected to reach US$ 10.99 Billion by 2033, growing at a CAGR of 3.7% during the forecast period 2025-2033
The most recent report published by DataM Intelligence indicates that the "Kidney Transplant Market" is likely to accelerate significantly in the next few years. The Kidney Transplant Market report gives a purposeful depiction of the area by the practice for research,…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
